Friday, Syros Pharmaceuticals Received Notice From Pfizer, As Successor To Global Blood Therapeutics, Exercising Its Right To Terminate An Agreement Dated December 17, 2019 Related To Sickle Cell Disease And Beta-thalassemia Therapies
Portfolio Pulse from Benzinga Newsdesk
Syros Pharmaceuticals received a notice from Pfizer, which has succeeded Global Blood Therapeutics, to terminate an agreement related to Sickle Cell Disease and Beta-thalassemia therapies. The termination will be effective from October 16, 2023.
July 24, 2023 | 9:20 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Syros Pharmaceuticals' agreement with Pfizer is being terminated. This could potentially impact Syros' development and commercialization of therapies.
The termination of the agreement with Pfizer could have a significant impact on Syros Pharmaceuticals, particularly if the agreement was a major part of their strategy for the development and commercialization of therapies.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Pfizer has decided to terminate its agreement with Syros Pharmaceuticals. This could potentially impact Pfizer's portfolio of therapies.
Pfizer's decision to terminate the agreement could potentially impact its portfolio of therapies. However, the extent of this impact is uncertain without more information on the importance of the terminated agreement to Pfizer's overall strategy.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70